48% (95%CI: 36-60%); the OCM rate in the untreated cohort was 9% (95%CI: 4-18%) figure 1. On multivariable analysis, untreated patients had higher risk to die from any cause (HR:2.63; 95%CI: 1.65,4.19; p<0.001) and experience CSM (HR:2.05; 95%CI: 1. 26,3.34; p[0.004).
INTRODUCTION AND OBJECTIVES: Fibroblast Growth Factor
Receptor 3 (FGFR3) is a potentially actionable target in bladder cancer (BC). FGFR3 mutations are associated with favorable prognosis in nonmuscle invasive (NMI) BC and MIBC. Over-expression of FGFR3 was reported in up to 40% of FGFR3 wild-type MIBC. p53 alterations rarely coincide with FGFR3 mutations. We analyzed FGFR3 mutations, protein-expression of FGFR3 and p53 and assessed their prognostic value in a multi-center, multi-laboratory setting.
METHODS: We included 1000 cN0M0, chemotherapy-naive patients who underwent radical cystectomy (RC) with pelvic node dissection. Specimens were reviewed by eight uro-pathologists. At seven laboratories, FGFR3 mutation status was examined using PCR-SNaPshot. p53 and FGFR3 expression were determined by immunohistochemistry (IHC). FGFR3 mutation status, p53 and FGFR3 protein expressions were correlated to each-other, clinicopathological parameters and disease-specific survival (DSS 
INTRODUCTION AND OBJECTIVES:
We sought to assess if pembrolizumab (pembro) improves the pathologic response rate in locally advanced urothelial carcinoma (UC) when combined with gemcitabine (G) and cisplatin (C) neoadjuvant chemotherapy (NAC) through a multicenter phase 1b/2 chemo-immunomodulation trial. Historically, the best pathologic non-muscle invasive rate (PaIR, pT1N0M0) has been noted for neoadjuvant dose dense MVAC at w44%.
METHODS: Cisplatin eligible patients with cT2-4aN0M0 UC were treated with pembro 200mg q3wks on day 8 for 5 doses; with C (70mg/m2) day 1, and G (1000mg/m2) days 1 and 8 of a 21-day cycle, for 4 cycles; followed by radical cystectomy (RC). Minimum criteria for evaluation of safety was one dose pembro and for efficacy two doses and RC. The primary endpoint was PaIR of !48%, and secondary endpoints included safety and tolerability, RC rate, relapse free-, disease specific-, and overall survival.
RESULTS: Forty patients (pts) were accrued: median age was 65 years, 75% were male, 10% had mixed UC histology, and PD-L1 combined positive score !10 was 52%. No dose-limiting toxicities were noted in the 6 pts on phase 1b. Average number of doses given (vs intended) for pembro [4.3(5), C[3.7(4), G[7.2(8) . There was 1 death on post-RC day 9 due to mesenteric ischemia. One pt did not have RC due to adverse event (AE), gr4 thrombocytopenic purpura; UC in remission at 14mo, and 3 patients refused RC. One pt with presumed gr3 MI during cycle 4 had a negative cardiac workup and completed therapy and RC without further AE. One gr4 hyponatremia and ten gr3 events did not preclude RC (2-each thromboembolism,
